Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Beyondspring Inc BYSI

Healthcare Biotechnology
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on using its technology platform for drug discovery and the development of therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being... see more

NDAQ:BYSI - Post Discussion

Beyondspring Inc > Compelling despite Headwinds
View:
Post by dmacd on Jan 12, 2022 10:07am

Compelling despite Headwinds

$90M cash vs $128M MC. Way too low for a company this advanced. FDA caused job losses in US with their approach. Would be nice to get some clarity on the issue but the reorg suggests it will take time.
Comment by dmacd on Jan 19, 2022 11:51am
Well if it goes to $3/sh or cash valuation then it is time for me to double down. I did not think that chance would come. The market is getting past stupid now. Beyond team has had a tough break with the FDA. I wonder if their China presence played a factor. The market deserves some clarity on the issue that the FDA has so hopefully we get that soon. China progression is still in play and the ...more  
Beyondspring Inc